Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
Year: 2020
Type: article
Study design: Observational Study
Abstract: Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms and structural brain measures using [ 11 C]UCB-J positron emission tomography in 18 patients with schizophrenia and 18 controls. We found significant group and group-by-region interaction effects on volume of distribution ( V T ). [ 11 C]UCB-J V T was significantly lower in the frontal and anterior cingulate cortices in schizophrenia with large effect sizes (Cohen’s d = 0.8-0.9), but there was no significant difference in the hippocampus. We also investigated the effects of antipsychotic drug administration on SV2A levels in Sprague-Dawley rats using western blotting, [ 3 H]UCB-J autoradiography and immunostaining with confocal microscopy, finding no significant effects on any measure. These findings indicate that there are lower synaptic terminal protein levels in schizophrenia in vivo and that antipsychotic drug exposure is unlikely to account for them.
Source: Nature Communications
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,380
Awards: G1601013279, MICA: Targeting neuro-inflammation in Schizophrenia, MRC Centre for Neurodevelopmental Disorders, Analysis of Mitochondrial Imaging Biomarkers in Neurodegenerative Disease, Neurobiological determinants of treatment response in psychosis., Beyond dopamine receptors in Schizophrenia - evaluating the role of Phosphodiesterase 10A in disease and treatment using PET imaging., Do antipsychotics inflame the brain?
OpenAlex ID: W2997938254
